From the submitted article: "The next step is to test thioridazine in clinical trials," and now that we know that, we know it's a bit early to say "without side effects," because thioridazine is a drug previously used in cancer trials,<p><a href="http://jpet.aspetjournals.org/content/263/1/186" rel="nofollow">http://jpet.aspetjournals.org/content/263/1/186</a><p><a href="http://cancerres.aacrjournals.org/content/50/17/5399" rel="nofollow">http://cancerres.aacrjournals.org/content/50/17/5399</a><p><a href="http://mutage.oxfordjournals.org/content/14/2/243.full" rel="nofollow">http://mutage.oxfordjournals.org/content/14/2/243.full</a><p>and yet it has not received wide use in cancer therapy. See "Warning Signs in Experimental Design and Interpretation"<p><a href="http://norvig.com/experiment-design.html" rel="nofollow">http://norvig.com/experiment-design.html</a><p>for cautions about overinterpreting press releases from a research group about preliminary research findings. It would be great to see new safe and effective therapies for cancer, and the way to find those will be to conduct careful clinical trials.